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Abstract 
The cystine/glutamate antiporter (system xc-) transports cystine into cell in exchange for glutamate. Fibroblast 
growth factor-2 (FGF-2) upregulates system xc- selectively on astrocytes, which leads to increased cystine 
uptake, the substrate for glutathione production, and increased glutamate release. While increased intracellular 
glutathione can limit oxidative stress, the increased glutamate release can potentially lead to excitotoxicity to 
neurons. To test this hypothesis, mixed neuronal and glial cortical cultures were treated with FGF-2. Treatment 
with FGF-2 for 48 h caused a significant neuronal deathin these cultures. Cell death was not observed in 
neuronal-enriched cultures, or astrocyte-enriched cultures, suggesting the toxicity was the result of neuron-glia 
interaction. Blocking system xc- eliminated the neuronal death as did the AMPA/kainate receptor 
antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione (NBQX), but not the NMDA receptor 
antagonist memantine. When cultures were exposed directly to glutamate, both NBQX and memantine blocked 
the neuronal toxicity. The mechanism of this altered profile of glutamate receptor mediated toxicity by FGF-2 is 
unclear. The selective calcium permeable AMPA receptor antagonist 1-naphthyl acetyl spermine(NASPM) failed 
to offer protection. The most likely explanation for the results is that 48 h FGF-2 treatment induces 
AMPA/kainate receptor toxicity through increased system xc- function resulting in increased release of 
glutamate. At the same time, FGF-2 alters the sensitivity of the neurons to glutamate toxicity in a manner that 
promotes selective AMPA/kainate receptor mediated toxicity. 
Abbreviations 
FGF-2 lactate dehydrogenase 
LDH lactate dehydrogenase 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide 
CPG (s)-4-carboxyphenylglycine 
SSZ sulfasalazine 
NBQX 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione 
NASPM 1-naphthyl acetyl spermine 
GSH glutathione 
EAAT excitatory amino acid transporter 
TBOA DL-threo-β-Benzyloxyaspartic acid 
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1. Introduction 
Fibroblast growth factor 2 (FGF-2), despite its discovery in fibroblasts, is widely expressed throughout the brain 
(Eckenstein et al., 1991a, Dono, 2003). FGF-2 acts on members of the FGF receptor family leading to activation 
of multiple intracellular pathways, including the PI3K/Akt and MEK/ERK pathways (Reuss and Bohlen und 
Halbach, 2003) and it has been demonstrated to be involved in development (Ohkubo et al., 2004), 
adult neurogenesis (Mudò et al., 2009), and tissue repair (Reuss and Bohlen und Halbach, 2003). Dysregulation 
of FGF-2 signaling has been implicated in acute and chronic neurodegenerative diseases. FGF-2 is upregulated by 
ischemic damage (Alzheimer and Werner, 2002) and traumatic brain injury (Mellergård et al., 2012), while FGF-2 
treatment is protective in Alzheimer's disease models (Mark et al., 1997). The role of FGF-2 in psychological 
disorders is complex, with alteration in FGF-2, FGF-2 receptors, and FGF-2 signaling 
pathways in schizophrenia, addiction, and major depression (Flores and Stewart, 2000, Evans et al., 
2004, Terwisscha van Scheltinga et al., 2010). FGF-2 was tested in clinical trials for the treatment for stroke but 
without success (Clark et al., 2000, Bogousslavsky et al., 2002). We have shown that FGF-2 upregulates system 
xc- (Liu et al., 2012), suggesting the possibility that some of the effects of FGF-2 may be through that action. 
 
System xc- is a cystine/glutamate antiporter on the cell membrane (Sato et al., 1995). Physiologically, system xc- 
takes up cystine and releases glutamate at a 1:1 ratio (Sato et al., 1999). The direction of transport is determined 
by the high glutamate levels and low cystine levels intracellularly. Once cystine is taken up it is rapidly reduced 
to cysteine, which can be used to synthesize glutathione (GSH), an important endogenous antioxidant in the 
brain (Meister and Anderson, 1983). GSH and cysteine can both be released into the extracellular space, 
typically by astrocytes, to regulate the redox state of the brain (Wang and Cynader, 2000, Dringen and Hirrlinger, 
2003). Also, the extracellular cysteine is taken up by neurons to synthesize GSH (Wang and Cynader, 
2000, Lewerenz et al., 2006, Escartin et al., 2011). The glutamate released by system xc- can have multiple 
effects. Glutamate is the most important excitatory neurotransmitter in the central nervous system. Glutamate 
released from astrocytes is believed to regulate synaptic activity and plasticity through activating parasynaptic 
and extrasynaptic receptors (Asztely et al., 1997, Hardingham et al., 2002). However, high extracellular 
glutamate levels can cause neuronal death through excitotoxicity, typically resulting from overactivation 
of NMDA receptors leading to excess calcium influx triggering cell death (Choi et al., 1987). An emerging theory 
is that activation of extrasynaptic NMDA receptors is particularly damaging (Hardingham and Bading, 2010). 
 
System xc- is widely expressed in the central nervous system (Sato et al., 2002, Burdo et al., 2006). Cell 
culture studies have shown that immature neurons rely on system xc- to take up cystine (Murphy et al., 1990). 
When immature neuronal cell cultures are incubated with high levels of glutamate, glutamate competitively 
inhibits cystine uptake through system xc- and the cells die from oxidative stress(Murphy et al., 1989). This 
mechanism of neuronal death is called oxidative glutamate toxicity (Schubert and Piasecki, 2001). This type of 
glutamate toxicity is distinct from glutamate toxicity in mature neuronal cells, which results from over-
stimulation of glutamate receptors leading to excitotoxicity (Choi et al., 1987). In mature cell cultures, neurons 
have low levels of system xc- activity, while astrocytes exhibit high levels of system xc- activity (Lobner, 2009). 
This shift of function indicates that as cells mature they take on more specialized tasks with astrocytes taking up 
cystine and releasing glutathione which is used by neurons (Fellin and Carmignoto, 2004, Stipursky et al., 
2011, Suzuki et al., 2011). In contrast to the enhancement of neurotoxicity by releasing glutamate, system xc- 
activity on non-neuronal cells can be protective to neurons. Overexpression of xCT in astrocytes has been shown 
to enhance glutathione release and protect neurons from oxidative stress (Shih et al., 2006). 
 
The dual actions of system xc- provide it with a unique potential for influencing cell fate. System xc- activity can 
be either beneficial or destructive depending on the cellular properties. If cells are undergoing oxidative stress, 
increasing system xc- activity should be protective as it increases cystine uptake, which contributes to increased 
antioxidant defense. However, if the cells are susceptible to excitotoxicity, increasing system xc- activity may be 
destructive by increasing extracellular glutamate and potentially causing excitotoxicity. 
 
In the present study, we used primary mixed neuronal and glial cortical cell cultures to investigate the effect of 
48 h FGF-2 treatment on neuronal survival/death. We have previously demonstrated that 24 h FGF-2 treatment 
upregulated system xc- activity on astrocytes. We demonstrate here that after system xc- is upregulated for a 
prolonged period of time, neuronal death occurs due to system xc- mediated excitotoxicity. 
2. Results 
2.1. Prolonged FGF-2 treatment induces neuronal death in mixed cortical cultures 
As reported previously (Liu et al., 2012), 24 h FGF-2 treatment of mixed neuronal and glial cultures did not cause 
any significant cell death. However, significant neuronal death was observed after 48 h of FGF-2 treatment (Fig. 
1). 
 
Fig. 1. FGF-2 induced toxicity occurs in mixed neuronal and glial cultures after 48 h treatment. Bars show 
% neuronal cell death (mean±s.e.m., n=24) quantified by measuring release of LDH, 24 and 48 h after the 
beginning of treatment with 100 ng/ml FGF-2. ⁎ indicates significant difference from control. 
 
The cell death following FGF-2 treatment for 48 h was observed in mixed neuronal and glial cultures, but not 
neuronal-enriched cultures (Fig. 2A) or glial-enriched cultures (Fig. 2B), suggesting an interaction of glia and 
neurons is necessary for FGF-2 induced neuronal death to occur. 
 
Fig. 2. FGF-2 does not induce toxicity after 48 h treatment in either neuronal-enriched or astrocyte-enriched 
cultures. A: Neuronal-enriched cultures. Bars show % neuronal death (mean±s.e.m., n==8) quantified by 
measuring release of LDH, 48 hours after the beginning of treatment with 100 ng/ml FGF-2. B: Astrocyte-
enriched cultures. Bars show % cell death (mean±s.e.m., n=16) quantified by measuring release of LDH, 48 h 
after the beginning of treatment with 100 ng/ml FGF-2. 
2.2. FGF-2 induced neuronal death is mediated by system xc- 
We have shown previously that 24 h FGF-2 treatment significantly increased system xc- activity selectively 
in astrocytes, with no effect on neuronal-enriched and microglial-enriched cultures (Liu et al., 2012). To 
determine whether FGF-2 upregulated system xc- function was still present after 48 h we measured 20 min 14C-
cystine uptake following 48 h FGF-2 treatment of astrocyte-enriched cultures. FGF-2 treatment doubled the 14C-
cystine uptake, and the uptake was mediated by system xc- as its inhibitor(s)-4-carboxyphenylglycine (CPG) 
completely blocked the increase (Fig. 3). 
 
Fig. 3. FGF-2 induced increase in cystine uptake is mediated by system xc-. Astrocyte-enriched cultures were 
exposed to FGF-2 (100 ng/ml) for 48 h, washed into a growth factor free media, and 14C-cystine uptake 
measured for 20 min with or without the system xc- antagonist (s)-4-carboxyphenylglycine (200 μM CPG). Bars 
show % control (mean±s.e.m., n=6). ⁎ indicates significant difference from control uptake. 
 
To assess whether system xc- was involved in the FGF-2 induced neuronal death, we tested the effects of the 
system xc- inhibitors CPG and sulfasalazine (SSZ) on neuronal death induced by 48 h FGF-2 treatment. 
Cotreatment of cells with either CPG or SSZ during the 48 h FGF-2 incubation prevented the neuronal death (Fig. 
4A). SSZ interferes with the LDH release assay, therefore the MTT metabolism assay was used to assess cell 
survival. While the effects of SSZ could not be tested by the LDH release assay, we did test CPG in this assay. 
Addition of CPG during the 48 h FGF-2 treatment was also protective by the LDH release assay (Fig. 4B). 
 
Fig. 4. FGF-2 induced neuronal death is prevented by blocking system xc-. Mixed neuronal and astrocytecultures 
were exposed to FGF-2 (100 ng/ml) with or without the system xc- antagonists (s)-4-carboxyphenylglycine 
(200 μM CPG) or sulfasalazine (300 μM SSZ) for 48 h. A: Bars show % cell survival(mean±s.e.m., n=8) quantified 
by measuring MTT reduction. B: Bars show % cell death (mean±s.e.m., n=8) quantified by measuring release 
of LDH. ⁎ indicates significant difference from control. 
2.3. AMPA/kainate, but not NMDA receptors, mediated the neuronal death 
System xc- mediates cystine uptake and glutamate release at the same time. Cystine uptake contributes to GSH 
synthesis which acts to decrease oxidative stress, therefore, it is unlikely that enhanced cystine uptake is 
responsible for the FGF-2 induced cell death. However, increasing glutamate release can lead to over-activation 
of glutamatergic receptors to cause excitotoxicity. To test this possibility, various glutamate receptor antagonists 
were tested to determine if they prevented FGF-2 induced neuronal death. The AMPA/kainate receptor 
antagonist NBQX, but not the NMDA receptor blocker memantine, blocked the FGF-2 induced neuronal death 
(Fig. 5A). In contrast to this result, both NBQX and memantine blocked neuronal death induced by direct 
addition of glutamate (Fig. 5B). One possibility for the results is that FGF-2 upregulates calcium 
permeable AMPA receptors making the neurons susceptible to AMPA receptor mediated toxicity. However, we 
did not observe any protection against neuronal death when cultures were cotreated with FGF-2 and various 
concentrations of the selective calcium permeable AMPA receptor antagonist 1-naphthyl 
acetyl spermine (NASPM) (Fig. 6). 
 
Fig. 5. Effects of the AMPA/kainate receptor antagonist NBQX or the NMDA receptor 
antagonist memantineon neuronal death induced by 48 hour exposure to FGF-2 or glutamate. A: FGF-2 
(100 ng/ml) treatment induced toxicity is attenuated by blocking AMPA receptors. B: Glutamate (15 μM) 
induced toxicity is attenuated by blocking AMPA/kainate or NMDA receptors. NBQX: 7.5 μM 2,3-dihydroxy-6-
nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione. MEM: 10 μM memantine. Bars show % neuronal cell 
death(mean±s.e.m., n=12) quantified by measuring release of LDH, 48 h after the beginning of the 
insult. ⁎indicates significant difference from control. # indicates significant difference from FGF-2 or glutamate 
treated. 
 
Fig. 6. FGF-2 induced toxicity is not mediated by calcium-permeable AMPA receptors. Mixed neuronal and glial 
cultures were exposed to FGF-2 (100 ng/ml) for 48 h with or without the calcium permeable AMPA receptor 
antagonist 1-naphthyl acetyl spermine (NASPM). Bars show % neuronal cell death (mean±s.e.m., n=8) quantified 
by measuring release of LDH, 48 hours after the beginning of the insult. ⁎ indicates significant difference from 
control. 
2.4. FGF-2 does not alter EAAT function 
One possibility for the glutamate receptor mediated neuronal death induced by FGF-2 is that it downregulates 
glutamate uptake leading to increased extracellular glutamate. We measured excitatory amino acid transporter 
(EAAT) activity using 3H-d-aspartate. The uptake of 3H-d-aspartate was attenuated by the general EAAT inhibitor 
DL-threo-β-Benzyloxyaspartic acid (TBOA). However, FGF-2 treatment for 24 or 48 h had no effect on 3H-d-
aspartate uptake (Fig. 7). 
 
Fig. 7. FGF-2 does not alter EAAT function. Astrocyte-enriched cultures were exposed to FGF-2 (100 ng/ml) for 
24 or 48 h, washed into a growth factor free media, and 3H-d-aspartate uptake measured for 20 min with or 
without the general EAAT inhibitor dl-threo-β-Benzyloxyaspartic acid (100 μM TBOA) present. Bars show % 
control (mean±s.e.m., n=8). ⁎ indicates significant difference from control uptake. 
3. Discussion 
This study examined the mechanism by which FGF-2 induces neuronal cell death in mixed neuronal and glial 
cultures, focusing on the role of its selective upregulation of system xc- on astrocytes. System xc- is of great 
interest because of its dual transport properties. Through uptake it provides cystine to the cells, which is 
converted intracellularly to cysteine, which is the rate limiting component for the formation of glutathione, the 
major antioxidant in the brain (Dringen et al., 2000, Dringen and Hirrlinger, 2003). In contrast, system xc- 
mediated glutamate release can lead to uncontrolled extracellular glutamate levels and 
enhance excitotoxicity (Fogal et al., 2007, Jackman et al., 2010). Both oxidative stress and excitotoxicity are 
involved in various neurodegenerative diseases and psychological disorders. Also, complex patterns of FGF-2 
dysregulation is observed in acute and chronic neurological disorders (Gaughran et al., 2006, Terwisscha van 
Scheltinga et al., 2010, Zechel et al., 2010). Therefore, it is possible that changes in system xc- function may be 
responsible for some of the actions of FGF-2. 
 
A balance between glutamate release from system xc- and glutamate uptake by EAATs is likely to determine 
whether extracellular glutamate reaches toxic levels. This is particularly important since it has been shown 
previously that FGF-2 can increase EAAT expression (Figiel et al., 2003). However, we failed to observe an 
increase in EAAT activity as measured by 3H-d-aspartate uptake. The lack of upregulation of EAAT function by 
FGF-2 in this system likely contributes to why FGF-2 induces toxicity. 
 
Our previous study showed that 24 h FGF-2 treatment resulted in an increase in cystine uptake through system 
xc- on astrocytes, with no effect on neuronal and microglial cystine uptake (Liu et al., 2012). The FGF-2 
treatment induced increase in system xc- was mediated through activation of FGFR1and required both MEK/ERK 
and PI3 kinase pathway activation. All of these cellular events happened without significant neuronal toxicity. 
However, in the current study we found that after 48 h FGF-2 treatment, significant neuronal cell death began to 
occur and this neuronal death was blocked by the system xc- antagonists CPG and SSZ. 
 
The role of system xc- in cell death has been investigated in different cell types and under different conditions. 
Inhibition of system xc- has been shown to be harmful to system xc- expressing cells. Oxidative glutamate 
toxicity was first described in immature neuronal cultures, in which system xc- is the major route of cystine 
uptake (Murphy et al., 1989, Murphy et al., 1990). Applying high concentrations of glutamate (millimolar range) 
to these immature neurons led to GSH depletion and eventually cell death from oxidative stress (Miyamoto et 
al., 1989, Murphy et al., 1989, Murphy and Baraban, 1990). Under these circumstances, increasing system xc- 
levels would likely be protective. 
 
However, increasing system xc- function is not always protective. Microglial system xc- activity has been shown 
to be toxic to surrounding cells (Domercq et al., 2007). Primary microglia activated by bacterial components 
have been shown to release enough glutamate through system xc- to kill neurons (Piani and Fontana, 1994) 
and oligodendrocytes (Domercq et al., 2005). The death of oligodendrocytes under these conditions was 
decreased by blocking AMPA/kainate receptors with CNQX (Domercq et al., 2005). This result is similar to what 
we have observed in primary mixed neuronal and glial cultures. The difference is that oligodendrocytes are 
normally sensitive to AMPA/kainate receptor toxicity (McDonald et al., 1998, Takahashi et al., 2003), while in 
cortical neurons, glutamate induced excitotoxicity is normally mediated primarily by activation of NMDA 
receptors (Choi et al., 1987, Choi, 1998). Although, this is not always that case, as the AMPA/kainate receptor 
antagonist NBQX was neuroprotective in an in vivo model involving lipopolysaccharide plus cystine induced 
neuronal death (Kigerl et al., 2012). 
 
Selectively increasing system xc- on astrocytes with IL-1β can also lead to increased glutamate release, which 
potentiates neuronal death induced by hypoglycemia and hypoxia (Jackman et al., 2010, Jackman et al., 2012), 
both of which are known to kill neurons in a process that involves over-activation of glutamatergic receptors 
(Snider et al., 1998, Czyz et al., 2002). The neuronal death in these conditions was largely attenuated by 
blocking NMDA receptors and was also decreased by inhibiting system xc- (Fogal et al., 2007, Jackman et al., 
2010, Jackman et al., 2012). Our data shows that FGF-2 treatment, like IL-1β, selectively increases system xc- 
activity on astrocytes (Liu et al., 2012). But FGF-2 treatment by itself induced neuronal cell death after system 
xc- activity was upregulated for 48 h. Also, the pharmacological profile of the excitotoxicity was different from 
non-FGF-2 treated neurons. While neuronal death induced by direct exposure of cultures to glutamate was 
blocked by either NMDA or AMPA/kainate receptor antagonists, FGF-2 induced neuronal death was only 
attenuated by the AMPA/kainate receptor antagonist. Interestingly, FGF-2 treatment has been shown to 
potentiate glutamate toxicity in PC-12 cells (Schubert et al., 1992). 
 
FGF-2 has been shown to change neuronal expression of both NMDA and AMPA receptors, and to alter 
sensitivity to NMDA receptor mediated toxicity both in vitro and in vivo. In cerebellar granule cells FGF-2 
treatment caused a time-dependent decrease in expression of NMDA receptor subunitsGluN2A and GluN2C with 
a decrease in NMDA-evoked calcium influx, while GluN1 and GluN2B levels were not changed (Brandoli et al., 
1998). FGF-2 pretreatment protected striatal neurons from NMDA receptor mediated toxicity (Freese et al., 
1992), while systematic administration of FGF-2 protected against intrastriatal injection of NMDA (Nozaki et al., 
1993a, Nozaki et al., 1993b). Also, FGF-2 treatment enhanced the rate of NMDA receptor inactivation in 
response to calcium influx in hippocampal neurons (Boxer et al., 1999). FGF-2 treatment decreased NMDA 
receptor levels in hippocampal cell cultures and elevations in intracellular calcium levels after glutamate 
exposure (Mattson et al., 1993). In contrast, FGF-2 treatment has been shown to increase AMPA receptor 
subunit GluA1 levels in the same cultures (Cheng et al., 1995). These results suggested the possibility that FGF-2 
induced neuronal death may be due to increase in the levels of GluA2 subunit lacking AMPA receptors, which 
have high calcium permeability (Bannerman et al., 2007). However, the selective antagonist of these calcium 
permeable AMPA channels, NASPM, failed to offer protection in our study. At concentrations above 5 μM, 
NASPM began to induce some toxicity by itself. However, the IC50 of NASPM for calcium-permeable AMPA 
receptors is 0.33 μM (Brackley et al., 1993). Therefore, the 5 μM concentration that was not toxic should have 
been an effective concentration. The most likely explanation of the results is that increased glutamate release 
from system xc- causes an AMPA/kainate receptor specific neuronal death because of attenuated NMDA 
receptor mediated toxicity induced by FGF-2 treatment. 
 
FGF-2 was a potential candidate for the treatment of stroke as it was shown to reduce ischemic damage, as well 
as, promote recovery and regeneration in multiple in vitro and animal models (Nozaki et al., 1993b, Rosenblatt 
et al., 1994, Song et al., 2002, Watanabe et al., 2004). However, in human clinical trials for stroke, FGF-2 not only 
failed to show any beneficial effect, it actually increased the mortality rate (Clark et al., 2000, Bogousslavsky et 
al., 2002). The reasons for FGF-2 being beneficial in animal models but not in human trials are not fully 
understood. One possibility is that the FGF-2 induced increase in system xc- activity, and the dual functions of 
system xc-, are responsible for the mixed actions of FGF-2 in the treatment of cerebral ischemia. The deciding 
factor for whether FGF-2 treatment is protective or injurious may be the importance of excitotoxicity and 
oxidative stress in each individual situation. FGF-2 administration has been shown to be beneficial in rodent 
studies in other disease models, such as depression (Turner et al., 2008c) and the rotenone model of Parkinson's 
disease (Hsuan et al., 2006). It is also possible that these beneficial effects may be mediated by the FGF-2 effect 
on system xc-, which leads to enhanced glutathione synthesis. In contrast, in the 6-hydroxydopamine model of 
Parkinson's disease there was decreased damage in mice lacking xCT (Massie et al., 2011). This result is 
consistent with system xc- function being damaging in that model. 
 
The dual amino acid transport function of system xc- allow it to regulate intracellular cystine and extracellular 
glutamate levels at the same time. Cystine taken up is broken down immediately to cysteine, which is a 
substrate for glutathione synthesis. While increasing cystine uptake can be protective by increasing the cells' 
antioxidant defense, glutamate released at the same time can potentially cause toxicity by over activating 
glutamatergic receptors. We show here that the net effect of long-term upregulation of system xc- selectively on 
astrocytes in mixed neuronal and glial cultures by FGF-2 treatment is negative. That is, the excitotoxicity 
component dominates, leading to neuronal death. 
4. Experimental procedures 
4.1. Materials 
Timed pregnant Swiss Webster mice were obtained from Charles River Laboratories (Wilmington, DE). Serum 
was from Atlanta Biologicals (Lawrenceville, GA). FGF-2 was from Alomone Labs (Jerusalem, Israel). 14C-cystine 
was from PerkinElmer (Waltham, MA). All other chemicals were obtained from Sigma (St. Louis, MO). 
4.2. Cortical cell cultures 
Mixed cortical cell cultures containing glial and neuronal cells were prepared from fetal (15–16 day gestation) 
mice as previously described (Lobner, 2000). Dissociated cortical cells were plated on 24-well plates coated with 
poly-d-lysine and laminin in Eagles' Minimal Essential Medium (MEM, Earle's salts, supplied glutamine-free) 
supplemented with 5% heat-inactivated horse serum, 5% fetal bovine serum, 2 mM glutamine and glucose (total 
21 mM). Neuron-enriched cultures were prepared exactly as above with the addition of 10 μM cytosine 
arabinoside 48 h after plating to inhibit glial replication. In these cultures <1% of cells are astrocytes (Dugan et 
al., 1995, Rush et al., 2010). Astrocyte-enriched cultures were prepared as described for mixed cultures except 
they are from cortical tissue taken from post-natal day 1–3 mice (Choi et al., 1987, Schwartz and Wilson, 
1992, Rush et al., 2010). Cultures were maintained in humidified 5% CO2 incubators at 37 °C. Mice were handled 
in accordance with a protocol approved by our institutional animal care committee and in compliance with the 
Public Health service Policy on Humane Care and Use of Laboratory Animals. All efforts were made to minimize 
animal suffering and reduce the number of animals used. 
4.3. Induction of neuronal death 
All experiments were performed on cultures 13–14 days in vitro (DIV). Cultures were exposed to different 
compounds for 48 h in media as described for plating except without serum. 
4.4. LDH release 
Cell death was assessed in mixed cultures by the measurement of lactate dehydrogenase (LDH) released from 
damaged or destroyed cells, in the extracellular fluid 48 h after the beginning of the insult. Control LDH levels 
were subtracted from insult LDH values and results normalized to 100% neuronal death caused by 
500 μM NMDA, or 100% cell death caused by 20 μM of the calcium ionophore A23187, added 24 h before the 
assay. Control experiments have shown previously that the efflux of LDH occurring from either necrotic or 
apoptotic cells is proportional to the number of cells damaged or destroyed (Koh and Choi, 1987, Lobner, 2000). 
Glial cell death (assessed by trypan blue staining) was not observed in any of the current studies involving mixed 
neuronal and glial cultures. 
4.5. MTT assay 
Cell survival was quantified by the measurement of the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) to produce a dark blue formazan product (Lobner, 2000). MTT was added to each 
well 48 h after the beginning of the insult to the cells. After 30-minute incubation, the medium was removed, 
and cells were dissolved in dimethyl sulfoxide. The formation of formazan was measured as the amount of 
reaction product by absorbance change at a wavelength of 590 nm by using a VersaMax tunable microplate 
reader (Molecular Devices, Sunnyvale, CA). Levels of formazan formation from cultures exposed to 500 μM 
NMDA (100% neuronal death) were subtracted from insult formazan levels, and results were normalized to a 
sham wash. 
4.6. 14C-cystine uptake 
14C-cystine uptake was assayed as previously described with modifications (Liu et al., 2009). FGF-2 was added to 
the serum containing media for the indicated durations. Cultures were then washed into HEPES buffered saline 
solution and immediately exposed to 14C-cystine (0.025 μCi/ml) for 20 min with or without CPG present. 
Following 14C-cystine exposure, cultures were washed with ice cold HEPES buffered saline solution and dissolved 
in 250 μl sodium dodecyl sulfate (0.1%). An aliquot (200 μl) was removed and added to scintillation fluid for 
counting. Values were normalized to 14C-cystine uptake in untreated control on the same experimental plate. 
4.7. 3H-d-aspartate uptake 
To assess EAAT function, uptake of radiolabeled d-aspartate into cultures was measured. FGF-2 was added to 
the serum containing media for the indicated durations. Cultures were then washed into HEPES buffered saline 
solution and immediately exposed to 3H-d-asparate (0.25 μCi/ml) for 20 min with or without 100 µM of the 
general EAAT inhibitor dl-threo-β-Benzyloxyaspartic acid (TBOA) present. Following 3H-d-aspartate exposure, 
cultures were washed, dissolved, and scintillation counted as for 14C-cystine studies. 
4.8. Statistical analysis 
Differences between test groups were examined for statistical significance by means of one-way ANOVA 
followed by the Bonferroni correction post-hoc test, with p<.05 being considered significant. 
Recommended articlesCiting articles (10) 
References 
Alzheimer and Werner, 2002 C. Alzheimer, S. Werner Fibroblast growth factors and neuroprotection Adv. Exp. 
Med. Biol., 513 (2002), pp. 335-351 
Asztely et al., 1997 F. Asztely, G. Erdemli, D.M. Kullmann Extrasynaptic glutamate spillover in the hippocampus: 
dependence on temperature and the role of active glutamate uptake Neuron, 18 (1997), pp. 281-293 
Bannerman et al., 2007 
P. Bannerman, M. Horiuchi, D. Feldman, A. Hahn, A. Itoh, J. See, Z.P.Jia, T. Itoh, D. Pleasure GluR2-free 
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptors intensify demyelination in 
experimental autoimmune encephalomyelitis J. Neurochem., 102 (2007), pp. 1064-1070 
Brackley et al., 1993 P.T. Brackley, D.R. Bell, S.K. Choi, K. Nakanishi, P.N. Usherwood Selective antagonism of 
native and cloned kainate and NMDA receptors by polyamine-containing toxins J. Pharmacol. Exp. 
Ther., 266 (1993), pp. 1573-1580 
Brandoli et al., 1998 C. Brandoli, A. Sanna, M.A. De Bernardi, P. Follesa, G. Brooker, I.Mocchetti Brain-derived 
neurotrophic factor and basic fibroblast growth factor downregulate NMDA receptor function in 
cerebellar granule cells J. Neurosci., 18 (1998), pp. 7953-7961 
Bogousslavsky et al., 2002 
J. Bogousslavsky, S.J. Victor, E.O. Salinas, A. Pallay, G.A. Donnan, C. Fieschi, M. Kaste, J-
M.M. Orgogozo, A. Chamorro, A. Desmet Fiblast (trafermin) in acute stroke: results of the European–
Australian phase II/III safety and efficacy trial Cerebrovasc. Dis., 14 (2002), pp. 239-251 
Boxer et al., 1999 A.L. Boxer, H. Moreno, B. Rudy, E.B. Ziff FGF-2 potentiates Ca(2+)-dependent inactivation of 
NMDA receptor currents in hippocampal neurons J. Neurophys., 82 (1999), pp. 3367-3377 
Burdo et al., 2006 J. Burdo, R. Dargusch, D. Schubert Distribution of the cystine/glutamate antiporter system 
xc- in the brain, kidney, and duodenum J. Histochem. Cytochem., 54 (2006), pp. 549-557 
Cheng et al., 1995 B. Cheng, K. Furukawa, J.A. O'Keefe, Y. Goodman, M. Kihiko, T. Fabian, M.P. Mattson Basic 
fibroblast growth factor selectively increases AMPA-receptor subunit GluR1 protein level and 
differentially modulates Ca2+ responses to AMPA and NMDA in hippocampal neurons J. 
Neurochem., 65 (1995), pp. 2525-2536 
Choi, 1998 D. Choi Antagonizing excitotoxicity: a therapeutic strategy for stroke? Mt. Sinai J. Med., 65 (1998), 
pp. 133-138 
Choi et al., 1987 D.W. Choi, M. Maulucci-Gedde, A.R. Kriegstein Glutamate neurotoxicity in cortical cell culture 
J. Neurosci., 7 (1987), pp. 357-368 
Clark et al., 2000 W.M. Clark, J.D. Schim, S.E. Kasner, S.J. Victor Trafermin in acute ischemic stroke: results of a 
phase II/III randomized efficacy study Neurology, 54 (2000), p. A88 
Czyz et al., 2002 A. Czyz, G. Baranauskas, L. Kiedrowski Instrumental role of Na+ in NMDA excitotoxicity in 
glucose-deprived and depolarized cerebellar granule cells J. Neurochem., 81 (2002), pp. 379-389 
Domercq et al., 2005 M. Domercq, E. Etxebarria, A. Pérez-Samartín, C. Matute Excitotoxic oligodendrocyte 
death and axonal damage induced by glutamate transporter inhibition Glia, 52 (2005), pp. 36-46 
Domercq et al., 2007 M. Domercq, M.V. Sánchez-Gómez, C. Sherwin, E. Etxebarria, R. Fern, C. Matute System xc- 
and glutamate transporter inhibition mediates microglial toxicity to oligodendrocytes J. 
Immunol., 178 (2007), pp. 6549-6556 
Dono, 2003 R. Dono Fibroblast growth factors as regulators of central nervous system development and 
function Am. J. Physiol. Regul. Integr. Comp. Physiol., 284 (2003), pp. R867-R881 
Dringen et al., 2000 R. Dringen, J.M. Gutterer, J. Hirrlinger Glutathione metabolism in brain metabolic 
interaction between astrocytes and neurons in the defense against reactive oxygen species Eur. J. 
Biochem., 267 (2000), pp. 4912-4916 
Dringen and Hirrlinger, 2003 R. Dringen, J. Hirrlinger Glutathione pathways in the brain Biol. Chem., 384 (2003), 
pp. 505-516 
Dugan et al., 1995 L.L. Dugan, V.M. Bruno, S.M. Amagasu, R.G. Giffard Glia modulate the response of murine 
cortical neurons to excitotoxicity: glia exacerbate AMPA neurotoxicity J. Neurosci., 15 (1995), pp. 4545-
4555 
Eckenstein et al., 1991a F. Eckenstein, W.R. Woodward, R. Nish iDifferential localization and possible functions 
of aFGF and bFGF in the central and peripheral nervous systems Ann. NY Acad. Sci., 638 (1991), 
pp. 348-360 
Escartin et al., 2011 C. Escartin, S.J. Won, C. Malgorn, G. Auregan, A.E. Berman, P.-
C. Chen, N. Déglon, J.A. Johnson, S.W. Suh, R.A. Swanson Nuclear factor erythroid 2-related factor 2 
facilitates neuronal glutathione synthesis by upregulating neuronal excitatory amino acid transporter 
3 expression J. Neurosci., 31 (2011), pp. 7392-7401 
Evans et al., 2004 
S.J. Evans, P.V. Choudary, C.R. Neal, J.Z. Li, M.P. Vawter, H. Tomita, J.F.Lopez., R.C. Thompson, F. Meng, J
.D. Stead, D.M. Walsh, R.M. Myers, W.E. Bunney, S.J.Watson, E.G. Jones, H. Akil Dysregulation of the 
fibroblast growth factor system in major depression Proc. Natl. Acad. Sci. USA, 101 (2004), pp. 15506-
15511 
Fellin and Carmignoto, 2004 T. Fellin, G. Carmignoto Neurone-to-astrocyte signalling in the brain represents a 
distinct multifunctional unit J. Physiol., 559 (2004), pp. 3-15 
Figiel et al., 2003 M. Figiel, T. Maucher, J. Rozyczka, N. Bayatti, J. Engele Regulation of glial glutamate 
transporter expression by growth factors Exp. Neurol., 183 (2003), pp. 124-135 
Flores and Stewart, 2000 C. Flores, J. Stewart Basic fibroblast growth factor as a mediator of the effects of 
glutamate in the development of long-lasting sensitization to stimulant drugs: studies in the rat 
Psychopharmacology, 151 (2000), pp. 152-165 
Fogal et al., 2007 B. Fogal, J. Li, D. Lobner, L.D. McCullough, S.J. Hewett System x(c)- activity and astrocytes are 
necessary for interleukin-1 beta-mediated hypoxic neuronal injury J. Neurosci., 27 (2007), pp. 10094-
10105 
Freese et al., 1992 A. Freese, S.P. Finklestein, M. DiFiglia Basic fibroblast growth factor protects striatal neurons 
in vitro from NMDA-receptor mediated excitotoxicity Brain Res., 575 (1992), pp. 351-355 
Gaughran et al., 2006 F. Gaughran, J. Payne, P.M. Sedgwick, D. Cotter, M. Berry. Hippocampal FGF-2 and FGFR1 
mRNA expression in major depression, schizophrenia and bipolar disorder Brain Res. Bull., 70 (2006), 
pp. 221-227 
Hardingham and Bading, 2010 G.E. Hardingham, H. Bading Synaptic versus extrasynaptic NMDA receptor 
signalling: implications for neurodegenerative disorders Nat. Rev. Neurosci., 11 (2010), pp. 682-696 
Hardingham et al., 2002 G.E. Hardingham, Y. Fukunaga, H. Bading Extrasynaptic NMDARs oppose synaptic 
NMDARs by triggering CREB shut-off and cell death pathways Nat. Neurosci., 5 (2002), pp. 405-414 
Hsuan et al., 2006 S.-L. Hsuan, H.M. Klintworth, Z. Xia Basic fibroblast growth factor protects against rotenone-
induced dopaminergic cell death through activation of extracellular signal-regulated kinases 1/2 and 
phosphatidylinositol-3 kinase pathways J. Neurosci., 26 (2006), pp. 4481-4491 
Jackman et al., 2012 N.A. Jackman, S.E. Melchior, J.A. Hewett, S.J. Hewett Non-cell autonomous influence of the 
astrocyte system xc- on hypoglycaemic neuronal cell death ASN Neuro, 4 (2012), pp. 23-32 
Jackman et al., 2010 N.A. Jackman, T.F. Uliasz, J.A. Hewett, S.J. Hewett Regulation of system x(c)(-) activity and 
expression in astrocytes by interleukin-1β: implications for hypoxic neuronal injury Glia, 58 (2010), 
pp. 1806-1815 
Kigerl et al., 2012 
K.A. Kigerl, D.P. Ankeny, S.K. Garg, P. Wei, Z. Guan, W. Lai, D.M. McTigue, R. Banerjee, P.G. Popovich 
System x(c)(-) regulates microglia and macrophage glutamate excitotoxicity in vivo Exp. 
Neurol., 233 (2012), pp. 333-341 
Koh and Choi, 1987 J.Y. Koh, D.W. Choi Quantitative determination of glutamate mediated cortical neuronal 
injury in cell culture by lactate dehydrogenase efflux assay J. Neurosci. Methods, 20 (1987), pp. 83-90 
Lewerenz et al., 2006 J. Lewerenz, M. Klein, A. Methner Cooperative action of glutamate transporters and 
cystine/glutamate antiporter system Xc- protects from oxidative glutamate toxicity J. 
Neurochem., 98 (2006), pp. 916-925 
Liu et al., 2012 X. Liu, J. Resch, T. Rush, D. Lobner Functional upregulation of system xc- by fibroblast growth 
factor-2 Neuropharmacology, 62 (2012), pp. 901-906 
Liu et al., 2009 X. Liu, T. Rush, J. Zapata, D. Lobner Beta-N-methylamino-l-alanine induces oxidative stress and 
glutamate release through action on system Xc(-) Exp. Neurol., 217 (2009), pp. 429-433 
Lobner, 2009 D. Lobner Mechanisms of beta-N-methylamino-l-alanine induced neurotoxicity Amyotroph. 
Lateral Scler., 10 (Suppl. 2) (2009), pp. 56-60 
Lobner, 2000 D. Lobner Comparison of the LDH and MTT assays for quantifying cell death: validity for neuronal 
apoptosis J. Neurosci. Methods, 96 (2000), pp. 147-152 
Mark et al., 1997 R.J. Mark, J.N. Keller, I. Kruman, M.P. Mattson Basic FGF attenuates amyloid beta-peptide-
induced oxidative stress, mitochondrial dysfunction, and impairment of Na+/K+-ATPase activity in 
hippocampal neurons Brain Res., 756 (1997), pp. 205-214 
Massie et al., 2011 A. Massie, A. Schallier, S.W. Kim, R. Fernando, S. Kobayashi, H. Beck, D.De 
Bundel, K. Vermoesen, S. Bannai, I. Smolder, M. Conrad, N. Plesnila, H. Sato, Y.Michotte Dopaminergic 
neurons of system x(c)−-deficient mice are highly protected against 6-hydroxydopamine-induced 
toxicity FASEB J., 25 (2011), pp. 1359-1369 
Mattson et al., 1993 M.P. Mattson, K.N. Kumar, H. Wang, B. Cheng, E.K. Michaelis Basic FGF regulates the 
expression of a functional 71 kDa NMDA receptor protein that mediates calcium influx and 
neurotoxicity in hippocampal neurons J. Neurosci., 13 (1993), pp. 4575-4588 
McDonald et al., 1998 J.W. McDonald, S.P. Althomsons, K.L. Hyrc, D.W. Choi, M.P. Goldberg Oligodendrocytes 
from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity Nat. 
Med., 4 (1998), pp. 291-297 
Meister and Anderson, 1983 A. Meister, M.E. Anderson Glutathione Annu. Rev. Biochem., 52 (1983), pp. 711-
760 
Mellergård et al., 2012 P. Mellergård, F. Sjögren, J. Hillman The cerebral extracellular release of glycerol, 
glutamate, and FGF2 is increased in older patients following severe traumatic brain injury J. 
Neurotrauma, 29 (2012), pp. 112-118 
Miyamoto et al., 1989 M. Miyamoto, T.H. Murphy, R.L. Schnaar, J.T. Coyle Antioxidants protect against 
glutamate-induced cytotoxicity in a neuronal cell line J. Pharmacol. Exp. Ther., 250 (1989), pp. 1132-
1140 
Mudò et al., 2009 G. Mudò, A. Bonomo, V. Di Liberto, M. Frinchi, K. Fuxe, N. Belluardo The FGF-2/FGFRs 
neurotrophic system promotes neurogenesis in the adult brain J. Neural. Transm., 116 (2009), pp. 995-
1005 
Murphy and Baraban, 1990 T.H. Murphy, J.M. Baraban Glutamate toxicity in immature cortical neurons 
precedes development of glutamate receptor currents Brain Res. Dev. Brain Res., 57 (1990), pp. 146-
150 
Murphy et al., 1989 T.H. Murphy, M. Miyamoto, A. Sastre, R.L. Schnaar, J.T. Coyle Glutamate toxicity in a 
neuronal cell line involves inhibition of cystine transport leading to oxidative stress Neuron, 2 (1989), 
pp. 1547-1558 
Murphy et al., 1990 T.H. Murphy, R.L. Schnaa, J.T. Coyle Immature cortical neurons are uniquely sensitive to 
glutamate toxicity by inhibition of cystine uptake FASEB J., 4 (1990), pp. 1624-1633 
Nozaki et al., 1993a K. Nozaki, S.P. Finklestein, M.F. Beal Delayed administration of basic fibroblast growth 
factor protects against N-methyl-d-aspartate neurotoxicity in neonatal rats Eur. J. 
Pharmacol., 232 (1993), pp. 295-297 
Nozaki et al., 1993b K. Nozaki, S.P. Finklestein, M.F. Beal Basic fibroblast growth factor protects against 
hypoxia–ischemia and NMDA neurotoxicity in neonatal rats J. Cereb. Blood Flow Metab., 13 (1993), 
pp. 221-228 
Ohkubo et al., 2004 Y. Ohkubo, A.O. Uchida, D. Shin, J. Partanen, F.M. Vaccarino Fibroblast growth factor 
receptor 1 is required for the proliferation of hippocampal progenitor cells and for hippocampal 
growth in mouse J. Neurosci., 24 (2004), pp. 6057-6069 
Piani and Fontana, 1994 D. Piani, A. Fontana Involvement of the cystine transport system xc- in the 
macrophage-induced glutamate-dependent cytotoxicity to neurons J. Immunol., 152 (1994), pp. 3578-
3585 
Reuss and Bohlen und Halbach von, 2003 B. Reuss, O. Bohlen und Halbach von Fibroblast growth factors and 
their receptors in the central nervous system Cell Tissue Res., 313 (2003), pp. 139-157 
Rosenblatt et al., 1994 S. Rosenblatt, K. Irikura, C.G. Caday, S.P. Finklestein, M.A. Moskowitz Basic fibroblast 
growth factor dilates rat pial arterioles J. Cereb. Blood Flow Metab., 14 (1994), pp. 70-74 
Rush et al., 2010 T. Rush, X.Q. Liu, J. Hjelmhaug, D. Lobner Mechanisms of chlorpyrifos and diazinon induced 
neurotoxicity in cortical culture Neuroscience, 166 (2010), pp. 899-906 
Sato et al., 1995 H. Sato, Y. Takenaka, K. Fujiwara, M. Yamaguchi, K. Abe, S. Bannai Increase in cystine transport 
activity and glutathione level in mouse peritoneal macrophages exposed to oxidized low-density 
lipoprotein Biochem. Biophys. Res. Commun., 215 (1995), pp. 154-159 
Sato et al., 1999 H. Sato, M. Tamba, T. Ishii, S. Bannai Cloning and expression of a plasma membrane 
cystine/glutamate exchange transporter composed of two distinct proteins J. Biol. Chem., 274 (1999), 
pp. 11455-11458 
Sato et al., 2002 H. Sato, M. Tamba, S. Okuno, K. Sato, K. Keino-Masu, M. Masu, S. Bannai Distribution of 
cystine/glutamate exchange transporter, system x(c)-, in the mouse brain J. Neurosci., 22 (2002), 
pp. 8028-8033 
Schubert et al., 1992 D. Schubert, H. Kimura, P. Maher Growth factors and vitamin E modify neuronal 
glutamate toxicity Proc. Natl. Acad. Sci., 89 (1992), pp. 8264-8267 
Schubert and Piasecki, 2001 D. Schubert, D. Piasecki Oxidative glutamate toxicity can be a component of the 
excitotoxicity cascade J. Neurosci., 21 (2001), pp. 7455-7462 
Schwartz and Wilson, 1992 J.P. Schwartz, D.J. Wilson Preparation and characterization of type 1 astrocytes 
cultured from adult rat cortex, cerebellum, and striatum Glia, 5 (1992), pp. 75-80 
Shih et al., 2006 A.Y. Shih, H. Erb, X. Sun, S. Toda, P.W. Kalivas, T.H. Murphy Cystine/glutamate exchange 
modulates glutathione supply for neuroprotection from oxidative stress and cell proliferation J. 
Neurosci., 26 (2006), pp. 10514-10523 
Snider et al., 1998 B.J. Snider, D. Lobner, K.A. Yamada, D.W. Choi Conditioning heat stress reduces excitotoxic 
and apoptotic components of oxygen-glucose deprivation-induced neuronal death in vitro J. 
Neurochem., 70 (1998), pp. 120-129 
Song et al., 2002 B.-W. Song, H.V. Vinters, D. Wu, W.M. Pardridge Enhanced neuroprotective effects of basic 
fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery 
vector J. Pharmacol. Exp. Ther., 301 (2002), pp. 605-610 
Stipursky et al., 2011 J. Stipursky, L. Romão, V. Tortelli, V.M. Neto, F.C.A. Gomes Neuron-glia signaling: 
Implications for astrocyte differentiation and synapse formation Life Sci., 89 (2011), pp. 524-531 
Suzuki et al., 2011 A. Suzuki, S.A. Stern, O. Bozdagi, G.W. Huntley, R.H. Walker, P.J.Magistretti, C.M. Alberini 
Astrocyte-neuron lactate transport is required for long-term memory formation Cell, 144 (2011), 
pp. 810-823 
Takahashi et al., 2003 J.L. Takahashi, F. Giuliani, C. Power, Y. Imai, V.W. Yong Interleukin-1beta promotes 
oligodendrocyte death through glutamate excitotoxicity Ann. Neurol., 53 (2003), pp. 588-595 
Terwisscha van Scheltinga et al., 2010 A.F. Terwisscha van Scheltinga, S.C. Bakker, R.S. Kahn Fibroblast growth 
factors in schizophrenia Schizophr. Bull., 36 (2010), pp. 1157-1166 
Turner et al., 2008c C.A. Turner, E.L. Gula, L.P. Taylor, S.J. Watson, H. Akil Antidepressant-like effects of 
intracerebroventricular FGF2 in rats Brain Res., 1224 (2008), pp. 63-68 
Wang and Cynader, 2000 X.F. Wang, M.S. Cynader Astrocytes provide cysteine to neurons by releasing 
glutathione J. Neurochem., 74 (2000), pp. 1434-1442 
Watanabe et al., 2004 
T. Watanabe, Y. Okuda, N. Nonoguchi, M.Z. Zhao, Y. Kajimoto, D.Furutama, H. Yukawa, M.-
A. Shibata, Y. Otsuki, T. Kuroiwa, S.-I. Miyatake Postischemic intraventricular administration of FGF-2 
expressing adenoviral vectors improves neurologic outcome and reduces infarct volume after 
transient focal cerebral ischemia in rats J. Cereb. Blood Flow Metab., 24 (2004), pp. 1205-1213 
Zechel et al., 2010 S. Zechel, S. Werner, K. Unsicker, O. Bohlen und Halbach von Expression and functions of 
fibroblast growth factor 2 (FGF-2) in hippocampal formation Neuroscientist, 16 (2010), pp. 357-373 
 
 
 
 
 
 
